Manufacturer Rifampicin factory
- FOB Price:Get Latest Price >
- Min.Order:25 Kg(s)
- Production Capacity:5000KG/month
- Payment Terms:L/C , T/T , PayPal
- Favorite
Business Type:Manufacturer
Country/Region:China
Ddu Verified
HOT Rank
6/10
NJC PHARMA
We are professional supplier of Rifampicin,Rifaximin,Simvastatin,Clindamycin,CoQ10,VB2 80%,SABAM.
Business Type:Manufacturer
Country/Region:China
Ddu Verified
HOT Rank
6/10
Rifampicin (also translated: pilosomycin, rifampicin, rifampicine, vefour Xian, rifampicin, Fu Ping or Leamy,
INN:Rifampicin) is a broad-spectrum antibiotic medicament belongs to rifamycin family, has strong antibacterial effect on Mycobacterium tuberculosis, also has curative effect the gram positive and negative bacteria, virus, etc.. Crystalline powder of red or dark red, insoluble in water. Usually capsules or tablets of oral medicine, combined with other anti - tuberculosis drugs to play a synergistic effect, and delay the production of resistant strains. It is mainly used for the treatment of tuberculosis, meningitis and Staphylococcus aureus infection. External use can be used to treat trachoma.
Specification
Rifampicin | CAS13292-46-1 | Brand: NJC PHARMA |
MW:822.95 | MSDS: Avaiable | |
MF : C43H58N4O12 | Sample: Avaiable | |
Category:Anti-inflammatory drug | Min order: 25kg | |
Quality standard : EP/USP/BP/CP/JP | Place of Origin:China | |
Introduction | Rifampicin is a bactericidal antibiotic drug of the rifamycin group. | |
Character | A red crystalline powder | |
Applications | Pharmaceutical raw materials |
Function and Application
The product used in combination with other anti-TB drugs initial treatment and retreatment of various tuberculosis, including tuberculous meningitis treatment. 2. the product used in combination with other drugs leprosy, non-tuberculous mycobacterial infections. 3. The goods and vancomycin (intravenous) can be combined for methicillin resistant Staphylococcus aureus caused serious infections. Rifampicin and erythromycin joint programs can be used to Legionella serious infections. 4. for asymptomatic carriers of Neisseria meningitidis to eliminate Neisseria meningitidis nasopharynx; but not for Neisseria meningitidis infection.